| Date Filed | Type | Description |
| 07/25/2018 |
GN
| CounterPath Reports Fourth Quarter and Fiscal 2018 Financial Results |
| 01/24/2018 |
GN
| CounterPath Announces Closing of Private Placement |
| 01/24/2018 |
GN
| CounterPath Announces Private Placement |
| 12/13/2017 |
GN
| CounterPath Reports Second Quarter Fiscal 2018 Financial Results |
| 11/16/2017 |
GN
| CounterPath Announces Distribution Agreement with India-based TaraSpan |
| 11/15/2017 |
GN
| Estech Systems, Inc. (ESI) Selects CounterPath for Its UC Softphone Solution |
| 11/01/2017 |
GN
| CounterPath Awarded Patent that Changes How Users Will Leverage Presence and Location to Intelligently Route Real-Time Communications Across Mobile and IP Networks |
| 10/02/2017 |
GN
| CounterPath Announces Bria SDK to Power Voice in a Leading Health Care Solution |
| 09/14/2017 |
GN
| CounterPath Announces Voting Results for Election of Directors |
| 09/14/2017 |
GN
| CounterPath Reports First Quarter Fiscal 2018 Financial Results |
| 02/25/2014 |
SC 13D/A
| SAFEGUARD SCIENTIFICS INC reports a 0% stake in NuPathe Inc. |
| 02/24/2014 |
SC 13G/A
| GLAXOSMITHKLINE PLC reports a 0% stake in NUPATHE INC. |
| 02/24/2014 |
SC 13D/A
| Quaker BioVentures II LP reports a 0% stake in NuPathe Inc. |
| 02/24/2014 |
SC 13D/A
| GAMCO INVESTORS, INC. ET AL reports a 0% stake in NuPathe Inc. |
| 02/21/2014 |
8-K
| Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Fa... |
| 02/21/2014 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 02/21/2014 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 02/14/2014 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 02/14/2014 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 02/14/2014 |
SC 13G/A
| GLAXOSMITHKLINE PLC reports a 12% stake in NUPATHE INC. |
| 02/13/2014 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 02/11/2014 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 02/11/2014 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 02/10/2014 |
SC 13G/A
| Foundation Asset Management, LP reports a 0% stake in NuPathe Inc. |
| 02/10/2014 |
SC 13G
| Foundation Asset Management, LP reports a 5.8% stake in NuPathe Inc. |
| 02/04/2014 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 02/04/2014 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 01/30/2014 |
SC 13D
| GAMCO INVESTORS, INC. ET AL reports a 3.9% stake in NuPathe Inc. |
| 01/23/2014 |
SC 14D9
| Form SC 14D9 - Solicitation, recommendation statements: |
| 01/23/2014 |
SC TO-T
| Form SC TO-T - Tender offer statement by Third Party: |
| 01/21/2014 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party: |
| 01/21/2014 |
SC14D9C
| Form SC14D9C - Written communication relating to third party tender offer: |
| 01/21/2014 |
SC14D9C
| Form SC14D9C - Written communication relating to third party tender offer: |
| 01/21/2014 |
8-K
| Acquisition/merger/asset purchase announced|
Docs:
|
"Agreement and Plan of Merger, by and among Teva",
"Form of Contingent Cash Consideration Agreement, by and among Train Merger Sub, Inc., American Stock Transfer & Trust Company and Teva Pharmaceuticals Industries Ltd",
"Subordinated Promissory Note, issued by NuPathe Inc. to Teva Pharmaceuticals USA Inc",
"Subordination Agreement, by and among Teva Pharmaceuticals USA, Inc., NuPathe Inc. and Hercules Technology Growth Capital, Inc",
"NuPathe Terminates Agreement with Endo and Enters into Agreement to be Acquired by Teva" |
|
|